Introduction
Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer mortality in women in both developed and developing countries. The World Health Organization estimates that more than 508,000 women died of breast cancer in 2011 [1] . Approximately 5-10% of women have metastatic breast cancer (MBC) at diagnosis [2] , while a further 20-40% of breast cancer patients will go on to develop MBC [3] . MBC is an incurable disease with a median survival of 2-3 years [4] [5] [6] .
Therefore, the aims of treatment are palliative: to control symptoms in order to maintain and improve patient quality of life (QoL) and, where possible, prolong survival [4] .
MBC is a highly heterogeneous disease varying in tumour presentation and in biological and clinical behaviour. There are several molecular subtypes of MBC. Tumours may vary by hormone receptor status (i.e. oestrogen receptor [ER] and progesterone receptor [PR] status) and human epidermal growth factor receptor 2 [HER2] status [7] . Approximately two-thirds of breast cancer tumours express ER and/or PR receptors [8] . Hormone receptor positive tumours can be further sub-divided into luminal A and luminal B molecular subtypes, with luminal B tumours having a poorer prognosis (median survival 30 vs 45 months) [6, 9] . Treatment options include hormonal therapies and selective oestrogen receptor modulators [8] . About 15-20% of newly diagnosed breast cancers over-express HER2 (HER2+) [10] [11] [12] . These patients are treated with HER2-targeting agents (e.g. trastuzumab), in combination with hormonal therapy and/or chemotherapy [10] [11] [12] . HER2-targeting therapies have been shown to improve survival in patients with MBC [10] . In patients who are HER2-negative, but hormone receptor positive with no extensive and/or symptomatic visceral disease, hormone therapy is the first-line treatment option. In those patients with visceral involvement, chemotherapy is usually the treatment of choice [2, 13] . Triple-negative tumours do not express ER, PR and HER2, and for these patients chemotherapy is the main treatment option. According to European Society of Medical Oncology (ESMO) guidelines, there are no standard approaches for triple-negative patients requiring second-or later-line chemotherapy [2] . Beyond the use of HER2 and hormone receptor status to guide treatment, there is currently limited progress. The use of molecular profiles to select appropriate treatment options is the subject of intense research and has great potential, but is likely to be sensitive to the emerging plethora of targeted therapies. Chemotherapy options include anthracyclines (e.g. doxorubicin, epirubicin), taxanes (e.g. docetaxel, nab-paclitaxel, and paclitaxel), vinca alkaloids (e.g. vinorelbine), anti-metabolites (e.g. capecitabine), platinum agents (e.g. cisplatin and carboplatin) and eribulin.
Treatment options for patients with MBC are dependent on several factors including disease burden, earlier treatments, response to and time elapsing since last exposure to earlier therapies, and patient characteristics and preferences [2, 13, 14] . Due to the heterogeneity of the disease, an individualised approach to the treatment of MBC is considered necessary. Following the failure of first-line therapy for MBC, the chance of response to subsequent therapy is reduced by approximately 50% with each previous regimen received [14] . However, due to the lack of predictive factors for specific agents, in some cases it is possible to see a larger than expected therapeutic benefit in second-line and/or further lines of therapy. Single-agent chemotherapy is the preferred treatment option in patients without severely symptomatic or immediately life-threatening disease [2] . In addition, treatment options in the second-and later-line settings are often limited by drug resistance as a result of earlier exposure to cytotoxic regimens [15] . For example, patients receiving second-line treatment for MBC will often have previously received a taxane and/or anthracycline-based chemotherapy, which may subsequently result in treatment-resistant cases of MBC.
At present there is no 'gold standard' of treatment for MBC [14] . Physicians must rely on clinical trial data to make decisions regarding the most beneficial course of treatment for patients following firstline therapy failure [15] . In this respect, well-designed, objective, randomised controlled trials (RCTs) are fundamental to informing clinical practice. However, the majority of trials tend to focus on the comparison of specific treatments in pre-defined patient populations at a specific phase of disease, and also have relatively short follow-up periods, producing MBC populations that are not representative of those seen in clinical practice [16] . There is therefore a need for physicians to understand the current evidence base for single-agent therapy for HER2-negative MBC second-line treatment.
The present systematic review (SR) was conducted in order to qualitatively synthesise the evidence base for the treatment of MBC and to make recommendations regarding future trials in this setting.
Methods

Search strategy
The present SR was performed in accordance with Cochrane recommendations [17] . A pre-defined SR protocol was produced. The original SR searches were run in the electronic databases of would not be direct comparators, but are included as they may still be used in second-line therapy.
Topoisomerase inhibitors were not included; amrubicin as it is unlicensed in MBC, and irinotecan because it is unlicensed in breast cancer. Also excluded were hormonal treatments (aromatase inhibitors), marimastat (due to its development having been terminated), tyrosine kinase inhibitors (lapatinib, reatinib, afatinib, BMS-754807, sunitinib, pazopanib, dasatinib) and inhibitors of downstream targets (everolimus, BKM120, BEZ-235, tanespimycin, retaspimycin, AUY922).
Outcome measures
The SR focused on the following efficacy outcomes: overall survival (OS), progression free survival (PFS), and time to progression (TTP). Data for QoL and other patient-reported outcomes were also sought. The following toxicity outcomes were included: withdrawal from treatment due to toxicity, haematological adverse events (AEs), non-haematological AEs, Grade three and four AEs, and mortality.
Data collection
A reviewer conducted the database searches and screening of citation abstracts for inclusion, according to a pre-defined SR protocol. Following abstract screening, full publications of potentially includable studies were retrieved for further review against the protocol eligibility criteria.
Inclusion/exclusion of citations was verified by another reviewer. Any disputes regarding eligibility were referred to a third reviewer. Study methodology, patient characteristics, and clinical outcomes data of included studies were extracted into a pre-determined data extraction table produced using Microsoft Excel ® . Quality appraisal of the elements of selection, attrition, detection, and performance bias was performed in accordance with the NICE Guidelines Manual 2009 [18] , which assesses risk of bias at the study level.
Results
A PRISMA flow diagram of the citation screening for the original and updated SRs is shown in second-and/or later-line papers, five [19] [20] [21] [22] [23] reported data for a purely second-line patient population, three [24] [25] [26] reported data from mixed-line treatment but provided results for the second-line subgroup separately, three [27] [28] [29] had unclear second-line status (i.e. it was unclear whether the previous therapy had been given in the adjuvant or metastatic setting), two [30, 31] reported data from second-or later-line patients, and one [32] reported data from a second-or later-line subgroup An overview of the patient characteristics across treatment arms is shown in Table 2 . [20] ; the proportion of patients with visceral metastases was numerically higher on mitomycin vs paclitaxel in Dieras et al, 1995 [21] ; and median age was slightly higher in the epirubicin arm vs doxorubicin in Gasparini et al, 1991 [22] .
There was much variation between trials with regards to the proportion of patients with visceral metastases, ( Table 2) : from 38% in Gasparini et al, 1991 [22] to 95% in Dieras et al, 1995 [21] for any visceral metastases; from 19-61% for liver metastases; and 26-61% for lung metastases. There was also considerable variation in the number of metastatic disease sites. Hormone receptor status also varied across trials, ER positivity ranging from 30-56%, and PR positivity from 5.6-30%, where reported.
Outcomes reported
The primary endpoint was OS in two trials [26, 30] , PFS in four [19, 27, 29, 31] , overall response in three [23, 28, 32] and not reported in five papers published between 1990 and 2000 [20-22, 24, 25] ( Table 1 ). Safety/toxicity was typically a secondary endpoint, amongst others. Only three papers examined QoL as an endpoint: one from Canada [24] provided QLQ-C30 data, one [26] in Finland used the Rotterdam Symptom Checklist and the recent, mainly European, TANIA trial [19] did not report the patient-reported outcome (PRO) data in the 2014 paper, the authors stating that PRO data would be reported separately, as would the final OS analysis and third-line PFS and third-line safety after further follow-up of trial patients. Neither Norris et al, 2000 [24] nor Joensuu et al, 1998 [26] reported the QoL data separately for the second-line subgroup.
Overall survival in second-and later-line setting
Median OS according to treatment line is shown in Table 3 and have been due in part to more than 80% of patients being third-or later-line within the metastatic setting, all patients being anthracycline-resistant and also to patients' HER2 status being unknown.
Although this study had OS as a primary objective, no statistically significant difference was observed between the arms, although this may have been influenced by the small sample size and extensive crossover at progression.
There was no OS data for weekly paclitaxel (PTX), and the majority of papers unfortunately did not report the 95% confidence interval around the median OS estimate. No RCT used modern adjustment methods to account for crossover of patients from the control arm, such as Rank Preserving Structural Failure Time (RPSFT) or Inverse Probability Censoring Weighted (IPCW) analyses [33] .
Progression-free survival in second-and later-line setting
Median PFS was reported in four trials [19, 27, 29, 31, 34] . [31] .
Time to progression
Of seven trials reporting TTP, three showed a significantly longer TTP: 3-weekly paclitaxel showed benefit over mitomycin (median TTP 3.5 vs 1.6 months, respectively; p=0.026) [21] ; capecitabine + sorafenib was superior to capecitabine alone (median TTP 6.8 vs 4.1 months, respectively; HR 0.56
[95% CI: 0.39, 0.8]; p=0.001) [29] ; and nab-paclitaxel was associated with significantly greater TTP vs standard paclitaxel q3w (median TTP 4.8 vs 3.7 months, respectively; HR 0.73; p=0.02) [32] .
No benefit in terms of TTP was demonstrated for doxorubicin + vinorelbine vs doxorubicin monotherapy (TTP 4.3 vs 5.3 months, respectively) [24] , for pegylated liposomal doxorubicin vs vinorelbine or mitomycin C + vinblastine (p>0.05) [31] , for 3-weekly docetaxel vs vinorelbine (2.4 vs 1.7 months, respectively; p=0.82) [30] , or for epirubicin vs epirubicin + vindesine (TTP 6 months in both treatment arms) [25] .
Grade III+ adverse events, discontinuation and safety summary
An overview of key safety results is shown in Table 5 . Of the treatments or treatment combinations showing significant efficacy benefit, the only treatment with a demonstrated better overall safety profile was nab-paclitaxel vs 3-weekly standard paclitaxel [32] : although grade III sensory neuropathy occurred more frequently with nab-paclitaxel (10% vs 2%, respectively), treatment-related grade IV neutropenia was significantly lower on nab-paclitaxel (9% vs 22%, p<0.001), there were no grade III/IV hypersensitivity reactions with nab-paclitaxel (despite being no premedication in this arm)
whereas there were such reactions with standard paclitaxel (with premedication given), and AErelated discontinuations and dose reductions or delays were low in both arms (3% with nab-paclitaxel and 7% on standard paclitaxel), as was febrile neutropenia (<2% in both arms).
Low-dose (60mg/m 2 ) docetaxel + capecitabine concomitantly, which had shown a PFS benefit vs docetaxel 70mg/m 2 (prior to sequential capecitabine) showed non-significantly reduced haematological AEs, higher frequency of hand-foot syndrome (7.4% vs 0%, respectively) and lower frequencies of fatigue and peripheral oedema (Table 5 ) [27] . Paclitaxel 3qw had shown increased TTP vs mitomycin, but the safety profile was difficult to interpret because although taxane therapy was associated with more frequent grade III/IV neutropenia & peripheral neuropathy, patients received substantially more courses of PTX than mitomycin [21] . Thrombocytopenia was more common with mitomycin [21] . Sorafenib added to capecitabine had shown increased TTP and PFS, but was associated with a significantly higher frequency of grade III/IV hand-foot syndrome (44% vs 14% with monotherapy capecitabine) and discontinuation due to AEs (mainly hand-foot syndrome and diarrhoea) were higher also (20% vs 9%, respectively) [29] . The addition of bevacizumab to (mainly) capecitabine was beneficial to PFS, yet Grade III/IV AEs were more common with the combination treatment, mainly due to higher incidences of grade III hypertension and proteinuria. Discontinuation was also higher with the combination (Table 5 ) [19] .
Risk of bias assessment of second-and later-line trials (n=14)
Of the 14 RCTs, 13 were full papers and so could be assessed for quality. Seven reported efficacy data on an intention-to-treat basis [19, 24, 25, 29, 31, 32, 34] , randomisation was carried out appropriately in five [19, 22, 24, 26, 29, 34] , but concealment of treatment allocation was unclear in most trials. Only one trial was double-blinded [29] and almost all trials did not have blinded outcome assessors. In terms of the distribution of patient characteristics between treatment groups, slight imbalances in potential prognostic factors were noted in six trials [20] [21] [22] [23] [24] 29] . Few trials reported confidence intervals around point estimates and only three confirmed HER2-negative status at enrolment. No trial assessed or commented on discordant HER2 status between the primary tumour and metastases.
Discussion
To the best of our knowledge, this is the first SR to have been conducted to identify RCT evidence for the single-agent treatment of HER2-negative MBC at the second-line stage. Limited data are available for this setting: commercial sponsors are not enthusiastic; the market diminishes in size; and measurable outcomes are small. In addition, there is a clinical heterogeneity that accumulates due to prior treatment, performance status, and patient preferences. Only 14 trials reported data separately or were exclusively conducted in the second-or later-line setting.
OS has long been regarded as the 'gold standard' measurement of clinical benefit in RCTs and is considered the primary measure of benefit in oncology [35] . Improvement in median OS is also considered an important outcome to determine clinical benefit of a new treatment compared with standard-of-care in the ASCO value framework proposed for advanced disease [36] . OS advantage is not easily demonstrable in this setting as the majority of RCTs are not usually sufficiently powered to detect OS benefits [37] , longer follow-up is required [35] , and estimates can be influenced by subsequent treatments once a particular trial has ended [37] , details of which may not have been collected and reported.
Of five trials demonstrating efficacy benefit (OS, PFS and/or TTP), only one showed significantly increased OS: nab-paclitaxel vs standard paclitaxel in the second-and later-line setting [32] . The survival benefit with nab-paclitaxel was realised with significantly less treatment-related grade IV neutropenia, and low levels of febrile neutropenia and AE-related discontinuation. The mature OS data from TANIA [19] , examining the addition of bevacizumab to single-agent chemotherapy, are awaited. Much of the variation in absolute OS estimates can be explained by differences in the characteristics of enrolled patients, including ECOG status, crossover effects (not adjusted for) and whether second-or third-line patients were enrolled.
All of the larger trials had good aspects of quality, including intention-to-treat analysis. Although all
were open-label, concealment of treatment allocation was largely not detailed and outcome assessors were not blinded. In two of the trials [31, 32] , the randomisation method was not fully detailed, in that the sequence generation was not discussed. However both studies used stratification and there was no evidence of any imbalance between the treatment arms.
As physicians rely on RCT data when deciding the most appropriate treatment for MBC patients failing first-line therapy [15] , there is a need for high-quality RCT evidence specifically in the secondline treatment of HER2-negative MBC patients, including OS estimation with adjustment for crossover effects [33] , QoL estimation, and an understanding of patient preferences at this stage (whether the highest efficacy is of primary concern or whether the better safety profile of a singleagent therapy is preferred).
Two recent reviews in MBC have been published, Palumbo et al, 2013 [16] and Partridge et al, 2014 [38] , the latter providing the basis for the latest ASCO clinical practice guideline for 'Chemo-and targeted therapy for women with HER2-negative (or unknown) advanced breast cancer' [39] . In this study, the search strategy was limited to publications from 1993 onwards and did not include searching of the electronic database Embase; therefore this SR did not identify nine studies [20-26, 30, 32] , and most notably Gradishar et al. 2005 [32] , demonstrating statistically significant OS benefit for nab-paclitaxel vs paclitaxel, was omitted from the ASCO guidelines [39] . Also not searched was
PubMed for e-publications ahead of print, which identified the TANIA trial [19] in our SR.
In Palumbo 2013, the search strategy is not detailed. Of the 14 trials we identified, Palumbo identified four [24, 26, 31, 32] .
We did not include the IMELDA trial (Gligorov et al, 2014 [40] ) as it focuses on maintenance of first- [41] as the only data reported specifically for the second-and later-line subgroup (n=85) was the clinical benefit rate, which was 51% with nab-paclitaxel (n=43) and 33% with standard paclitaxel (n=42), p=0.181.
Outcomes of interest (OS, PFS, TTP and safety) were not reported for the second-or later-line subgroup.
Classification of the line of therapy also appeared to be defined differently in these reviews than in our SR. Partridge et al, 2014 [38] included two studies as second-line; Cortes et al, 2011 [34] that was excluded from our SR because it enrolled patients with 2-5 prior chemotherapy treatments with two or more prior regimens for advanced disease and therefore represented a third-or later-line setting, and
Keller et al, 2004 [31] that we classified as 'second-or later-line' because it enrolled patients with 'no more than two chemotherapy regimens in the advanced setting (excluding adjuvant setting)' and so would have included some third-line patients. Two other studies [27, 29] , were classified as secondline, whereas we classified these as uncertain second-line therapy as it was unclear if the second-line label related to chemotherapies or to the setting within metastatic disease. In Palumbo et al, 2013 [16] , the line of therapy is seemingly classified according to the number of lines overall rather than by the number of lines within metastatic disease, meaning that the trials included are of a more heterogeneous nature than in our SR, as they will include trials with some patients who are first-line in the MBC setting. These distinctions are of importance as they help to better explain the OS and PFS data observed and, if papers provide not only median estimates but also the 95% confidence interval, then clinicians and patients will have more informative data on progression after failure of first-line treatment of metastatic disease upon which to base their treatment decision.
One limitation to the methods employed in this SR is that, due to time constraints, we were only able to perform the second search update from October 2013 in PubMed, rather than conducting it in all the electronic databases. Comparison of outcomes between trials was hampered by the lack of common comparators across the evidence base, many of the single-agent therapies being compared with combination treatments, and heterogeneity (beyond line of therapy) being contributed further to by potential differential assignment of patients to trials, e.g. patients enrolled in capecitabine trials may, in general, have a lower disease burden than those in vinorelbine trials, varying chemotherapy exposure (e.g. per-protocol maximum number of cycles and the dose reduction criteria applied to manage toxicity events), and varying schedule and cumulative dose across a cycle (e.g. the cumulative dose of a taxane administered across a cycle is known to predict neurotoxicity, with the 3-weekly schedule having a lower cumulative dose than weekly administration [42] ). There was a distinct lack of QoL data that, in this setting, is a data gap, critical to be filled if clinical practice and patient decision-making is to be fully informed as well as reimbursement obtained [43] .
Conclusion
There are few RCTs conducted specifically in the second-line HER2-negative MBC setting. Nabpaclitaxel was the only single agent that demonstrated a survival advantage at the second-line and beyond. Few treatment options provide clinical benefit without adversely influencing tolerability.
Given that MBC is an incurable disease and that an equally important aim of treatment at this stage is to enhance QoL and enable patients to be at home with their families, it is vital that trial investigators and clinicians set standards for the design and conduct of clinical trials with this aim in mind, with patients enrolled according to the treatment line received within the metastatic setting, with sufficient sample size to enable outcomes to be estimated with greater precision, with HER2-negative status and any discordant status established, a non-invasive method that has recently been tested in phase I [44] , and with PROs recorded. This would contribute to physicians being able to more reliably inform patients regarding the likely range of treatment outcomes, and thereby help patients reach the treatment decision that is right for them.
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